CompletedNot Applicable

The Effect of Aerobic Exercise on Bone Turnover Markers in Postmenopausal Patients

Turkey (Türkiye)45 participantsStarted 2022-11-15

Plain-language summary

The aim of the study was to evaluate the effect of light-moderate aerobic exercise on BMD in postmenopausal osteopenic women using bone formation-resorption markers. Participants were randomized into two groups as aerobic exercise and control groups and followed for 12 weeks. At the beginning and at the 12th week, bone formation-resorption markers including procollagen type 1 N-terminal propeptide (P1NP), cross-linked C-telopeptide of type 1 collagen (CTX), osteocalcin, malondialdehyde, non-bone-specific total alkaline phosphatase, 25(OH)D3 and oxidative markers such as parathyroid hormone (PTH) were evaluated in serum and whether there was a difference between the 2 groups.

Who can participate

Age range

45 Years – 65 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Postmenopausal women from Türkiye aged 45-65 years, * Bone mineral density (BMD) T-scores between -1 and -2.5 ( measured by dual-energy X-ray absorptiometry) Exclusion Criteria: * Vertebral compression fracture, * A history of traumatic or nontraumatic fractures in the past year, * Thyroid hormone disorders, * Parathyroid hormone disorders, * Liver function disorders, * Kidney function disorders, * Chronic heart failure, * A history of malignancy, * A history of rheumatological diseases, * Corticosteroid use, * Immunosuppressive drug use, * Anticonvulsant and heparin use, * Antiresorptive or anabolic agent treatments use * Hormone replacement therapy use * Those who could not complete sessions due to mechanical pain exacerbated during aerobic exercise on a treadmill (such as knee and hip osteoarthritis, back pain, etc)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The serum levef of Procollagen type 1 N-terminal propeptide (P1NP) (ng/ml)

Timeframe: From enrollment to the end of treatment at 12 weeks

The serum levef of Cross-linked C-telopeptide of type I collagen (CTX) (ng/ml)

Timeframe: From enrollment to the end of treatment at 12 weeks

The serum levef of Osteocalcin(OCN) (ng/ml)

Timeframe: From enrollment to the end of treatment at 12 weeks

The serum levef of nonbone-specific total alkaline phosphatase (ALP) (U/L)

Timeframe: From enrollment to the end of treatment at 12 weeks

Trial details

NCT IDNCT06866561

SponsorBursa Yuksek Ihtisas Training and Research Hospital

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2023-11-15

View on ClinicalTrials.gov More Postmenopausal Osteopenia trials

Plain-language summary

Who can participate

Age range

45 Years – 65 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

The serum levef of Procollagen type 1 N-terminal propeptide (P1NP) (ng/ml)

Timeframe: From enrollment to the end of treatment at 12 weeks

The serum levef of Cross-linked C-telopeptide of type I collagen (CTX) (ng/ml)

Timeframe: From enrollment to the end of treatment at 12 weeks

The serum levef of Osteocalcin(OCN) (ng/ml)

Timeframe: From enrollment to the end of treatment at 12 weeks

The serum levef of nonbone-specific total alkaline phosphatase (ALP) (U/L)

Timeframe: From enrollment to the end of treatment at 12 weeks